Mainpointe patents expiration
1. Tuxarin Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6383471 | MAINPOINTE | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
Apr, 2019
(5 years ago) | |
| US6248363 | MAINPOINTE | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
Nov, 2019
(4 years ago) | |
| US9066942 | MAINPOINTE | Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer |
Jan, 2032
(7 years from now) | |
| US9107921 | MAINPOINTE | Oral dosage forms for oxygen containing active agents and oxyl-containing polymers |
Jan, 2032
(7 years from now) | |
Drugs and Companies using CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE ingredient
Market Authorisation Date: 22 June, 2015
Treatment: Treatment of cough and symptoms associated with upper respiratory allergies or a common cold with codeine phosphate and chlorpheniramine maleate orally administered extended release tablets
Dosage: TABLET, EXTENDED RELEASE;ORAL
More Information on Dosage
TUXARIN ER family patents
